Type 2 diabetes mellitus (T2DM) and obesity are metabolic disorders characterized by
excess cardiovascular risk. Glucagon-like peptide 1 (GLP1) receptor (GLP1R) agonists …

Traditional approaches to prevention of the complications of type 2 diabetes (T2D) and
obesity have focused on reduction of blood glucose and body weight. The development of …

Background Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to
reduce the risk of adverse cardiovascular events in patients with diabetes. Whether …

Aim To assess the effect of tirzepatide on long‐term risk of atherosclerotic cardiovascular
disease (ASCVD) among people with obesity or overweight without diabetes from …

In the last few decades, glucagon-like peptide-1 receptor (GLP-1R) agonists have changed
current guidelines and improved outcomes for individuals with type 2 diabetes. However, the …

In the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in major
adverse cardiovascular events in 17,604 adults with preexisting cardiovascular disease …

The prevalence of overweight and obesity has reached pandemic proportions. Obesity is
known to increase the risk for Type 2 diabetes and hypertension, as well as the risk for overt …

OBJECTIVE To determine whether semaglutide slows progression of glycemia in people
with cardiovascular disease and overweight or obesity but without diabetes. RESEARCH …

OBJECTIVE To determine the extent to which changes in plasma proteins, previously
predictive of cardiometabolic outcomes, predict changes in two diabetes remission trials …

Obesity is a prevalent global health issue affecting approximately half of the world's
population. Extensive scientific research highlights the urgent need for effective obesity …